此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

The Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]OD-001 in Healthy Male Participants

2026年11月2日 更新者:Odyssey Therapeutics, Inc.

An Open Label, Single-Dose, Single-Period Study Designed to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]OD-001 in Healthy Male Participants

This study looks at how the body handles an investigational drug called OD-001. Researchers want to learn how the medicine is absorbed, how it is broken down, and how it leaves the body.

About 8 healthy men will join the study, so that at least 6 people complete it. Each participant will drink a single dose of OD-001 as a liquid. This will be done on an empty stomach, so each participant will be asked not to eat for a period of time beforehand.

The medicine contains a small amount of a radioactive "tracer" (carbon-14). The tracer lets researchers follow the medicine and its breakdown products through your body. The amount of radioactivity is small and carefully limited. After the dose, researchers will collect samples such as blood, urine and stool. These will show how much of the medicine is recovered and what it turns into in the body.

研究概览

地位

招聘中

研究类型

介入性

注册 (估计的)

8

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

30年 至 65年 (成人、年长者)

接受健康志愿者

是的

有资格学习的性别

男性

描述

Inclusion Criteria:

  • Aged 30 to 65 years inclusive at the time of signing informed consent
  • Must agree to adhere to the contraception requirements. In addition, vasectomised male participants with partners of childbearing potential must have received medical assessment of the surgical success of the procedure Healthy male participants according to the assessment of the Investigator, as based on a complete medical history including a physical examination, vital signs, single 12-lead ECGs, and laboratory safety tests without any clinically significant abnormalities as measured at screening. ECGs and vital signs to be re-checked at pre-dose.
  • Body mass index (BMI) of 18.0 to 35.0 kg/m2 as measured at screening.
  • Must have regular bowel movements (i.e. average stool production of ≥1 and ≤3 stools per day).

Exclusion Criteria:

  • Presence or history of clinically significant allergy requiring treatment, as judged by the Investigator. Hay fever is allowed unless it is active.
  • History of clinically significant cardiovascular, renal, hepatic, dermatological, respiratory, particularly GI disease, especially peptic ulceration, clinically significant GI bleeding, UC, CD, Irritable Bowel Syndrome or malabsorption syndrome that may impair bioavailability, and neurological or psychiatric disorder
  • Participants who are unable to take oral medication.
  • Acute diarrhea, constipation or vomiting in the 7 days before the predicted Day 1. If screening occurs >7 days before Day 1his criterion will be determined on Day 1. Diarrhoea will be defined as the passage of liquid faeces and/or a stool frequency of greater than three times per day. Constipation will be defined as a failure to open the bowels more frequently than every other day

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:其他
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:[14C]OD-001

oral solution

[14C]OD-001

研究衡量的是什么?

主要结果指标

结果测量
大体时间
Mass balance recovery of total radioactivity in all excreta: CumAe
大体时间:Day 1 to Day 8
Day 1 to Day 8
Mass balance recovery of total radioactivity in all excreta: Cum%Ae
大体时间:Day 1 to Day 8
Day 1 to Day 8
Number of OD-001 metabolites at ≥10% of total exposure of [14C]-radiolabel in blood
大体时间:Day 1 to Day 8
Day 1 to Day 8
Identity of OD-001 metabolites at ≥10% of total exposure of [14C]-radiolabel in blood by LC-MS and NMR
大体时间:Day 1 to Day 8
Day 1 to Day 8

次要结果测量

结果测量
大体时间
Rate of elimination of [14C]OD-001 in excreta by Ae
大体时间:Day 1 to Day 8
Day 1 to Day 8
Rate of elimination of [14C]OD-001 in excreta by %Ae
大体时间:Day 1 to Day 8
Day 1 to Day 8
Secondary Rate of elimination of [14C]OD-001 in excreta by CumAe
大体时间:Day 1 to Day 8
Day 1 to Day 8
Rate of elimination of [14C]OD-001 in excreta by Cum%Ae by interval
大体时间:Day 1 to Day 8
Day 1 to Day 8
Incidence of treatment-emergent adverse events
大体时间:Day 1 to Day 8
Day 1 to Day 8
Percentage of [14C] total radioactivity OD-001 metabolites in excreta
大体时间:Day 1 to Day 8
Day 1 to Day 8
Tmax of OD-001 in blood, total radioactivity in blood and plasma
大体时间:Day 1 to Day 8
Day 1 to Day 8
Cmax of OD-001 in blood, total radioactivity in blood and plasma
大体时间:Day 1 to Day 8
Day 1 to Day 8
AUC0-last of OD-001 in blood, total radioactivity in blood and plasma
大体时间:Day 1 to Day 8
Day 1 to Day 8
T1/2 of OD-001 in blood, total radioactivity in blood and plasma
大体时间:Day 1 to Day 8
Day 1 to Day 8
Incidence of abnormal clinical laboratory test results
大体时间:Day 1 to Day 8
Day 1 to Day 8
Incidence of abnormal electrocardiograms (ECGs)
大体时间:Day 1 to Day 8
Day 1 to Day 8

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Sharan Sidhu, MBChB, BAO, MRCS, MFPM、Quotient Sciences
  • 研究主任:Anthony Opipari、Odyssey Therapeutics, Inc.

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年10月31日

初级完成 (估计的)

2026年12月1日

研究完成 (估计的)

2027年1月1日

研究注册日期

首次提交

2026年10月5日

首先提交符合 QC 标准的

2026年10月21日

首次发布 (实际的)

2026年10月28日

研究记录更新

最后更新发布 (实际的)

2026年11月5日

上次提交的符合 QC 标准的更新

2026年11月2日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

关键字

其他研究编号

  • OD-001-100

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

未定

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅